EUVIMEDEUVIMED entdecken
Crossref

A Comparative Observational Study on the Safety and Efficacy of Brimonidine Tartarate Versus Timolol Maleate in Glaucoma Patients

G. Sireesha, S.K. Shakeela, Y. V. L. Keerthy, E. Sai Chandu, R. Keerthi

International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)

DOI: 10.25258/ijcpr.18.5.247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von G. Sireesha und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the therapeutic effectiveness and safety profile of Brimonidine versus Timolol in glaucoma patients attending the ophthalmology outpatient department.

Objectives

1. To evaluate and compare the efficacy of brimonidine tartrate and timolol maleate in glaucoma patients by assessing reduction in intraocular pressure using Goldmann Applanation Tonometry (GAT) and changes in visual field parameters including Mean Deviation (MD), Pattern Standard Deviation (PSD), Visual Field Index (VFI), and Glaucoma Hemifield Test (GHT). 2. To assess and compare the safety and tolerability of brimonidine and timolol using Conjunctival Hyperaemia Grading (CHG) Scale, and Ocular Symptoms Score (OSS). 3. To evaluate structural optic nerve damage and disease progression by measuring the Cup–Disc Ratio (CDR). 4. To assess patient adherence to antiglaucoma therapy using the Medication Adherence Rating Scale (MARS-10). Methodology: It is a prospective comparative observational study. A total of 150 patients diagnosed with glaucoma attending the Ophthalmology Outpatient Department at Government General Hospital, Guntur were included in the study. Patients were divided into two groups: Brimonidine (n=75) and Timolol (n=75). Data were collected using a structured data collection form, including demographic details, clinical parameters, intraocular pressure measurements, visual field analysis, and adverse drug reactions.

Results

A total of 150 patients were included in the study, with 75 patients in each group. Both Brimonidine and Timolol showed significant reduction in intraocular pressure (IOP) within groups. However, when compared between groups, Brimonidine demonstrated a statistically significant greater reduction in IOP than Timolol, particularly in post-treatment values and percentage IOP reduction. Structural assessment using cupdisc ratio also showed significantly better optic nerve preservation in the Brimonidine group. Visual field parameters were largely comparable between the two groups, with only selective parameters showing significant differences. Medication adherence was similar in both groups with no statistically significant difference. Ocular symptoms and conjunctival hyperemia were more frequently observed in the Brimonidine group, although most were mild to moderate in severity.

Conclusion

Both Brimonidine and Timolol are effective in reducing intraocular pressure in patients with glaucoma. However, Brimonidine demonstrated significantly greater efficacy in lowering IOP and showed better outcomes in optic nerve head preservation compared to Timolol. Despite a higher incidence of mild ocular side effects, Brimonidine may be considered a more effective therapeutic option for achieving stronger disease control. The choice of treatment should be individualized based on patient tolerance, safety profile, and clinical condition, with careful consideration of the balance between efficacy and tolerability.

Zitieren

APA

Sireesha, G., Shakeela, S., Keerthy, Y. V. L., Chandu, E. S., & Keerthi, R. (2026). A Comparative Observational Study on the Safety and Efficacy of Brimonidine Tartarate Versus Timolol Maleate in Glaucoma Patients. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.247

Vancouver

Sireesha G, Shakeela S, Keerthy YVL, Chandu ES, Keerthi R. A Comparative Observational Study on the Safety and Efficacy of Brimonidine Tartarate Versus Timolol Maleate in Glaucoma Patients. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.247

BibTeX
@article{Sireesha2026,
  author = {Sireesha, G. and Shakeela, S.K. and Keerthy, Y. V. L. and Chandu, E. Sai and Keerthi, R.},
  title = {A Comparative Observational Study on the Safety and Efficacy of Brimonidine Tartarate Versus Timolol Maleate in Glaucoma Patients},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {05},
  doi = {10.25258/ijcpr.18.5.247}
}
Kostenlos starten →